title: Preventing thrombophilia-related complications of pregnancy: an update.
abstract: Approximately half of all pregnancy-related venous thromboembolic events are associated with thrombophilia. Although the most compelling data for a link between thrombophilia and other adverse pregnancy outcomes derive from women with antiphospholipid antibodies, some studies also suggest an association between these pregnancy complications and hereditary thrombophilias. Management of thrombophilia often involves anticoagulant therapy; however, use of these agents during pregnancy is challenging. There is a paucity of high-quality studies and consequently, recommendations are based largely on extrapolation from data in nonpregnant women, in addition to observational studies and a few small randomized studies. This article will review the impact of the thrombophilias on pregnancy and its outcome, evidence for therapies aimed at the prevention of thrombophilia-related pregnancy complications, and the most recent recommendations contained in the 9th Edition of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
authors.affiliation: Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute (TaARI), Hamilton, ON, Canada. batesm@mcmaster.ca
authors.forename: Shannon M
authors.initials: SM
authors.lastname: Bates
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000097:blood; D000925:Anticoagulants / Q000627:therapeutic use; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000517:prevention & control; D012307:Risk Factors; D019851:Thrombophilia / Q000150:complications / Q000188:drug therapy*; D054556:Venous Thromboembolism / Q000188:drug therapy / Q000209:etiology
chemical_list: D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight